片仔癀(600436.SH):九龍江集團擬將2.98%股份無償劃轉至漳州國有資本運營
格隆匯6月2日丨片仔癀(600436.SH)公佈,2022年6月1日,九龍江集團與漳州國有資本運營簽訂《關於漳州片仔癀藥業股份有限公司的國有股份無償劃轉協議》,九龍江集團擬將其持有的公司1800.00萬股(佔公司總股本2.98%)無償劃轉至全資子公司漳州國有資本運營。此次國有股份無償劃轉事宜已取得漳州市國有資產監督管理委員會同意。
此次國有股份無償劃轉後,九龍江集團及其一致行動人漳州國有資本運營、漳州國有資產投資合計持有公司332,040,455股,佔公司總股本55.04%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.